1. Teva Pharmaceutical Industries Ltd., ‘Health and Digital Behaviours’ Survey, August 2017
Teva is among the top 15 global pharmaceutical companies globally, delivering high-quality, patient-centric healthcare solutions used by approximately 200 million patients in 60 markets every day. Teva produces a leading innovative treatment for multiple sclerosis and has late-stage development programs for a range of disorders of the central nervous system, including movement disorders, migraine, pain and neurodegenerative conditions. With its European headquarters in Amsterdam, the Netherlands, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a broad range of products in nearly every therapeutic area. Teva draws on its specialty and generics capabilities to seek new ways of addressing unmet patient needs by combining drug development with devices, services and technologies. Teva's net revenues in 2016 were $21.9 billion. For more information, visitwww.tevapharm.com.
<div class="block banner-nhs"><div class="banner-nhs__content">Teva Europe news, press releases & media contacts </div> <div class="banner-nhs__button"><a class="banner-nhs__link" href="http://tevaeurope.com/news">Go to home</a></div></div>
Registered office: Teva Pharmaceuticals Europe BV,
Piet Heinkade 107, 1019 GM Amsterdam,